In fact, CPT1A is the mediator of the increased lipid oxidation in T-cells exposed to the PD1 checkpoint inhibition, strongly suggesting that metabolic reprograming of the T-cells in tumors is a promising approach that could be used to re-activate the immune system and invigorate anti-tumor immunity. Here, CPT1A is linked to neoplasm.